IDM Foresees Junovan Approval In 2007 Following Pre-NDA Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm preps response to FDA info request, gears for 2006 filing of bone cancer therapy.
You may also be interested in...
IDM Junovan Has August User Fee Date For Osteosarcoma
Treatment has orphan drug status, but was not granted a priority review by FDA.
Mobile Health Apps Could Disrupt Medical Technology Market– Report
Ernst & Young annual report highlights the importance of emerging “patient-empowering” and “information-leveraging” technologies, and their power to drive health care efficiencies.